Overview

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Status:
Not yet recruiting

Trial end date:
2022-10-30

Target enrollment:

Participant gender:

Summary

XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.

Phase:

Phase 2

Details

Lead Sponsor:

Sciwind Biosciences APAC CO Pty. Ltd.

Collaborator:

Hangzhou Sciwind Biosciences Co., Ltd.

Treatments:

Glucagon
Glucagon-Like Peptide 1
Liraglutide